TY - JOUR
T1 - Neoadjuvant chemotherapy and hormonal therapy followed by radical prostatectomy
T2 - Feasibility and preliminary results
AU - Pettaway, Curtis A.
AU - Pisters, Louis L.
AU - Troncoso, Patricia
AU - Slaton, Joel
AU - Finn, Laury
AU - Kamoi, Kazumi
AU - Logothetis, Christopher J.
N1 - Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2000/3
Y1 - 2000/3
N2 - Purpose: We assessed the feasibility and efficacy of integrating chemotherapy and androgen ablation with radical prostatectomy in patients with locally advanced prostate cancer. The neoadjuvant approach was adopted because it allows an in situ assessment of antitumoral activity. Patients and Methods: Thirty-three patients were enrolled who met the clinical criteria of stage T1-2, Gleason score of ≥ 8 or T2b-T2c, Gleason score of 7 and prostate-specific antigen (PSA) level greater than 10 ng/mL (n = 15), or clinical stage T3 (n = 18). Therapy consisted of 12 weeks of ketoconazole and doxorubicin alternating with vinblastine, estramustine, and androgen ablation followed by prostatectomy. The ability of neoadjuvant chemotherapy and hormonal therapy to induce a 20% rate of pT0 in the prostatectomy specimen as well as surgical feasibility were assessed. Results: Chemotherapy complications were comparable to those reported with this regimen previously. No major intraoperative complications occurred. Post-operative complications occurred in 10 (33%) of 30 patients. One patient died at home after discharge (postoperative day 17; no autopsy was performed). Ten (33%) of the 30 patients had organ-confined disease, and 20 (70%) of 30 had extraprostatic extension; 11 (37%) of the 30 had positive lymph nodes. Only five (17%) of 30 exhibited positive surgical margins. All patients achieved an undetectable PSA level postoperatively, and 20 of the surviving 29 patients remain without disease recurrence with a median follow-up of 13 months (range, 9 to 18 months). Conclusion: Chemotherapy and androgen ablation followed by radical prostatectomy was feasible in patients with locally advanced prostate cancer. Although the goal of achieving a 20% rate for pT0 status was not achieved, we believe this type of integrated therapeutic strategy should be investigated further for its ability to alter the course of regionally advanced prostate cancer. (C) 2000 by American Society of Clinical Oncology.
AB - Purpose: We assessed the feasibility and efficacy of integrating chemotherapy and androgen ablation with radical prostatectomy in patients with locally advanced prostate cancer. The neoadjuvant approach was adopted because it allows an in situ assessment of antitumoral activity. Patients and Methods: Thirty-three patients were enrolled who met the clinical criteria of stage T1-2, Gleason score of ≥ 8 or T2b-T2c, Gleason score of 7 and prostate-specific antigen (PSA) level greater than 10 ng/mL (n = 15), or clinical stage T3 (n = 18). Therapy consisted of 12 weeks of ketoconazole and doxorubicin alternating with vinblastine, estramustine, and androgen ablation followed by prostatectomy. The ability of neoadjuvant chemotherapy and hormonal therapy to induce a 20% rate of pT0 in the prostatectomy specimen as well as surgical feasibility were assessed. Results: Chemotherapy complications were comparable to those reported with this regimen previously. No major intraoperative complications occurred. Post-operative complications occurred in 10 (33%) of 30 patients. One patient died at home after discharge (postoperative day 17; no autopsy was performed). Ten (33%) of the 30 patients had organ-confined disease, and 20 (70%) of 30 had extraprostatic extension; 11 (37%) of the 30 had positive lymph nodes. Only five (17%) of 30 exhibited positive surgical margins. All patients achieved an undetectable PSA level postoperatively, and 20 of the surviving 29 patients remain without disease recurrence with a median follow-up of 13 months (range, 9 to 18 months). Conclusion: Chemotherapy and androgen ablation followed by radical prostatectomy was feasible in patients with locally advanced prostate cancer. Although the goal of achieving a 20% rate for pT0 status was not achieved, we believe this type of integrated therapeutic strategy should be investigated further for its ability to alter the course of regionally advanced prostate cancer. (C) 2000 by American Society of Clinical Oncology.
UR - http://www.scopus.com/inward/record.url?scp=0033993630&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033993630&partnerID=8YFLogxK
U2 - 10.1200/jco.2000.18.5.1050
DO - 10.1200/jco.2000.18.5.1050
M3 - Article
C2 - 10694556
AN - SCOPUS:0033993630
SN - 0732-183X
VL - 18
SP - 1050
EP - 1057
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
IS - 5
ER -